Mechanisms of fibrosis in post-surgical lymphedema
术后淋巴水肿纤维化的机制
基本信息
- 批准号:10063531
- 负责人:
- 金额:$ 89.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAnimalsAntigensAwardAxillary Lymph Node DissectionB-LymphocytesBacterial AntigensBiopsy SpecimenCD4 Positive T LymphocytesCell Differentiation processCellsChronicClinicalClone CellsDendritic CellsDevelopmentDiseaseDisease ProgressionEstrogensEventExtracellular MatrixFemaleFibrosisFormulationFunctional disorderGenerationsGoalsImmune Response GenesImmune responseImmunityImmunologyImpairmentIn VitroInflammationInflammatoryInflammatory ResponseInjuryKnockout MiceKnowledgeLeadLymphangiogenesisLymphaticLymphatic Endothelial CellsLymphatic SystemLymphatic functionLymphedemaMastectomyMediatingMissionModelingNeoplasm MetastasisNitric OxideNitrogenOperative Surgical ProceduresOxidative StressOxygenPathologicPathologyPatientsPharmaceutical PreparationsPharmacologyPlayPodoconiosisPositioning AttributePrevention strategyProcessPublicationsPublishingReactionResearchRiskRoleSamplingSecondary toSeveritiesSignal TransductionSingle Nucleotide PolymorphismSkinSourceSpecimenSurgical InjuriesT cell receptor repertoire sequencingT cell responseT-LymphocyteTestingTissuesTopical applicationTransforming Growth Factor betaTransgenic AnimalsTranslatingUnited States National Institutes of HealthWorkautoreactive T cellbasebench to bedsidecancer cellcancer complicationcancer therapycardiovascular injurychemokineclinical practiceclinically relevantcytokinedesignefficacy studyevent cyclefirst-in-humangenome wide association studyhigh riskimmunotherapy trialsinnovationinvestigator-initiated trialkeratinocytelipid metabolismlymphatic dysfunctionlymphatic vasculaturelymphatic vesselmacrophagemalemigrationmouse modelmultidisciplinaryneutralizing antibodynovelnovel therapeuticspalliativepre-clinicalpreventrepairedresponsesecondary lymphedemaskin disordersmall molecule inhibitortherapy developmenttreatment strategytumor
项目摘要
Project Summary
This proposal is significant because we aim to develop novel treatments for secondary lymphedema, a common
and morbid complication of cancer treatment. This is important because current therapies for this disease are
palliative and inadequate. In our previous studies, we have shown that the pathology of lymphedema is
secondary to progressive fibrosis and is mediated by chronic T-helper (CD4+) cell inflammation and T-helper 2
(Th2) differentiation. We have used this information to develop novel therapies for the treatment of secondary
lymphedema and have recently translated our work from the bench to the bedside in an investigator-initiated trial
using Th2 cytokine neutralizing antibodies.
The objective of this application is to identify the cellular mechanisms that initiate CD4+ cell inflammatory
responses following lymphatic injury. This objective is a logical extension of our previous work and should identify
additional targets that can be targeted pharmacologically to treat/prevent lymphedema. Our long-term objective
is to use the information we gain from this basic understanding of lymphedema to develop therapies that disrupt
the cycle of events that promote progressive fibrosis and lymphatic dysfunction. Our approach is innovative
since we use a combination of mouse models and clinical specimens to dissect the cellular mechanisms of
lymphedema pathology. Our group is uniquely positioned to accomplish our goals on the basis of our
multidisciplinary team, our access to clinical tissues, and our novel mouse models. We plan to achieve our
objectives using 2 specific aims:
Aim 1. Determine how lymphatic injury activates CD4+ cells. This aim will use clinical samples and mouse
models to test the hypothesis that keratinocytes play a key role in the activation and migration of CD4+ cells to
lymphedematous tissues. In addition, we will test the hypothesis that single nucleotide polymorphisms in immune
response genes will increase the risk of lymphedema.
Aim 3. Determine how inflammation impairs lymphatic function. This aim will test the hypothesis that
inflammatory responses in lymphedema impair lymphatic function by multiple effects, including tissue and
lymphatic fibrosis, perilymphatic inflammation, and impaired formation of collateral lymphatic vessels.
项目摘要
这项建议意义重大,因为我们的目标是开发新的治疗继发性淋巴水肿的方法,这是一种常见的
以及癌症治疗的病态并发症。这一点很重要,因为目前治疗这种疾病的方法是
治标不治本,不称职。在我们之前的研究中,我们已经表明淋巴水肿的病理是
继发于进行性纤维化,由慢性辅助性T细胞炎症和辅助性T细胞2介导
(Th2)分化。我们已经利用这些信息开发了治疗继发性心脏病的新疗法。
淋巴水肿,最近在一项由研究人员发起的试验中将我们的工作从替补席上转移到了床边
使用Th2细胞因子中和抗体。
这项应用的目的是确定启动CD4+细胞炎症的细胞机制。
淋巴损伤后的反应。这一目标是我们以前工作的合乎逻辑的延伸,应该确定
可通过药物靶点治疗/预防淋巴水肿的其他靶点。我们的长期目标
是利用我们从淋巴水肿的基本理解中获得的信息来开发扰乱
促进进行性纤维化和淋巴功能障碍的事件循环。我们的方法是创新的
由于我们使用了小鼠模型和临床标本相结合的方法来剖析
淋巴水肿病理。我们的集团处于独特的地位,可以在我们的基础上实现我们的目标
多学科团队,我们对临床组织的访问,以及我们的新型小鼠模型。我们计划实现我们的
使用2个特定目标的目标:
目的1.确定淋巴损伤如何激活CD4+细胞。这一目标将使用临床样本和小鼠
验证角质形成细胞在CD4+细胞活化和迁移中发挥关键作用的假设的模型
淋巴水肿性组织。此外,我们将检验单核苷酸多态在免疫中的假设
反应基因会增加淋巴水肿的风险。
目的3.确定炎症如何损害淋巴功能。这一目标将检验这一假设
淋巴水肿中的炎症反应通过多种影响损害淋巴功能,包括组织和
淋巴管纤维化、淋巴管周围炎症和侧支淋巴管形成障碍。
项目成果
期刊论文数量(57)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Lymphatic Function Regulates Contact Hypersensitivity Dermatitis in Obesity.
- DOI:10.1038/jid.2015.283
- 发表时间:2015-11
- 期刊:
- 影响因子:0
- 作者:Savetsky IL;Albano NJ;Cuzzone DA;Gardenier JC;Torrisi JS;García Nores GD;Nitti MD;Hespe GE;Nelson TS;Kataru RP;Dixon JB;Mehrara BJ
- 通讯作者:Mehrara BJ
A Prospective Study on the Safety and Efficacy of Vascularized Lymph Node Transplant.
一项关于血管化淋巴结移植的安全性和有效性的前瞻性研究。
- DOI:10.1097/sla.0000000000005591
- 发表时间:2022-10-01
- 期刊:
- 影响因子:9
- 作者:
- 通讯作者:
Tissue-engineered lymphatic graft for the treatment of lymphedema.
用于治疗淋巴水肿的组织工程淋巴移植物。
- DOI:10.1016/j.jss.2014.07.059
- 发表时间:2014
- 期刊:
- 影响因子:0
- 作者:Kanapathy,Muholan;Patel,NikhilM;Kalaskar,DeepakM;Mosahebi,Afshin;Mehrara,BabakJ;Seifalian,AlexanderM
- 通讯作者:Seifalian,AlexanderM
Lymphedema and obesity: is there a link?
淋巴水肿和肥胖症:是否有联系?
- DOI:10.1097/prs.0000000000000268
- 发表时间:2014-07
- 期刊:
- 影响因子:3.6
- 作者:Mehrara BJ;Greene AK
- 通讯作者:Greene AK
Lymphatic Contribution to the Cellular Niche in Heterotopic Ossification.
- DOI:10.1097/sla.0000000000001619
- 发表时间:2016-12
- 期刊:
- 影响因子:9
- 作者:Loder S;Agarwal S;Sorkin M;Breuler C;Li J;Peterson J;Gardenier J;Hsieh HH;Wang SC;Mehrara BJ;Levi B
- 通讯作者:Levi B
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Babak J Mehrara其他文献
Babak J Mehrara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Babak J Mehrara', 18)}}的其他基金
Role of epidermis in regulating inflammatory skin manifestations of post-surgical lymphedema
表皮在调节术后淋巴水肿炎症性皮肤表现中的作用
- 批准号:
10606927 - 财政年份:2022
- 资助金额:
$ 89.73万 - 项目类别:
Molecular mechanisms of age-related lymphatic dysfunction
年龄相关淋巴功能障碍的分子机制
- 批准号:
10538995 - 财政年份:2022
- 资助金额:
$ 89.73万 - 项目类别:
Molecular mechanisms of age-related lymphatic dysfunction
年龄相关淋巴功能障碍的分子机制
- 批准号:
10665795 - 财政年份:2022
- 资助金额:
$ 89.73万 - 项目类别:
Restoration of lymphatic function in postsurgical lymphedema with lymph node transfer
通过淋巴结转移恢复术后淋巴水肿的淋巴功能
- 批准号:
9185953 - 财政年份:2015
- 资助金额:
$ 89.73万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
8532029 - 财政年份:2012
- 资助金额:
$ 89.73万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
8372995 - 财政年份:2012
- 资助金额:
$ 89.73万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
8695460 - 财政年份:2012
- 资助金额:
$ 89.73万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
9094645 - 财政年份:2012
- 资助金额:
$ 89.73万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 89.73万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 89.73万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 89.73万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 89.73万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 89.73万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 89.73万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 89.73万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 89.73万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 89.73万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 89.73万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)














{{item.name}}会员




